Bifogade filer
20231108_PM_Isofol_Nomination committee_final
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
The information in the press release is intended for investors.
According to the instructions for appointment of the nomination committee for Isofol Medical AB (publ), the nomination committee shall consist of three members, representatives appointed by the three largest shareholders in the company in terms of the number of votes based on the share register or other reliable information provided by Euroclear Sweden AB as of September 30, 2023. Another nomination committee member may be appointed by minority shareholders representing at least 10 percent of the votes. The chairman of the nomination committee shall consist of the largest shareholder in terms of votes at the time of the nomination committee's appearance, unless the nomination committee agrees otherwise, and may not consist of the chairman of the board or another board member. The chairman of the board shall not be part of the nomination committee, but is normally a co-opted member at its meetings.
The nomination committee ahead of the AGM 2024 consists of the following members:
- Göran Gustafsson, representing approximately 3.31 percent of the shares and votes,
- Johan Möller, appointed by Mats Franzén representing approximately 3.29 percent of the shares and votes, and
- Lars Lind, chairman of the nomination committee, appointed by Hans Enocson representing about 2.82 percent of the shares and votes
In addition, representatives of minority owners representing approximately 10.83 percent of votes and shares have appointed Matsola Palm.
The members of the nomination committee are appointed by owners who represent a total of about 20.25 percent of the total number of shares and votes in Isofol Medical AB (publ) according to the ownership conditions as of September 30, 2023.
Information about the nomination committee’s work and the instructions to the nomination committee can be found on the company website under the section for Corporate Governance. The nomination committee’s proposal will be presented in the summons to the annual general meeting 2024 and on the company’s website, www.isofolmedical.com.
Shareholders who wish to submit proposals to the nomination committee shall do this in writing by sending an e-mail to valberedningen@isofolmedical.com (heading: "Isofol's nomination committee") or by mail to the following address:
Isofol Medical AB (publ)
Att. Valberedningen
Arvid Wallgrens Backe 20
413 46 GOTHENBURG
SWEDEN
Any proposals must be received by the nomination committee no later than March 17, 2024, to be included in the notice and agenda for the Annual General Meeting 2024.
For more information, please contact
Mats Franzén, chairman of the board
E-mail: mats@efficere.se
Phone: +46 (0)704 47 29 09
Isofol Medical AB (publ)
Roger Tell, acting Chief Executive Officer
E-mail: roger.tell@isofolmedical.com
Phone: +46 (0) 760 29 39 11
The information was submitted for publication, through the agency of the contact person set out above, at 13:45 CET, on November 8, 2023.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.